Jervine Crystal Forms for Antitumor Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors associated with abnormal Hedgehog signaling pathway activation, such as basal cell carcinoma, lung cancer, and pancreatic cancer, lack effective and non-toxic inhibitors, and the bioavailability of jervine, a natural inhibitor, varies with its crystal forms, necessitating the characterization and stabilization of its crystal forms for improved drug formulation.
Innovation Solution
Characterization of two crystal forms of jervine (I and II) using X-ray powder diffraction and development of methods for their preparation, including mixing with menthanol or acetonitrile, to enhance bioavailability and stability, along with pharmacological testing demonstrating significant inhibition of the Hedgehog signaling pathway and antitumor effects in human tumor xenograft models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If jervine is used as an antitumor agent, then inhibition of Hedgehog signaling pathway is achieved, but bioavailability varies with crystal forms reducing drug efficacy consistency
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing different crystal forms (polymorphs) of jervine, where the physical state parameter (crystal structure) is changed to optimize bioavailability. Crystal form I and Crystal form II represent different solid-state arrangements of the same molecule, and the patent establishes that these different crystal forms have different bioavailability characteristics, allowing selection of the optimal form for consistent drug efficacy.
Solution Approach 2:
The patent utilizes phase transitions in the solid state by characterizing and stabilizing specific crystal forms of jervine. The development of controlled preparation methods for Crystal form I and Crystal form II allows transition between different solid phases, enabling optimization of pharmacokinetic properties and ensuring consistent bioavailability through controlled crystallization processes.
2Reliability
If crystal forms of jervine are characterized and stabilized, then bioavailability and stability are enhanced, but preparation complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-characterizing and defining specific crystal forms (Crystal form I and Crystal form II) with their distinct X-ray powder diffraction patterns established before clinical use. The preparation methods are developed in advance to reliably produce these specific crystal forms, ensuring stability and bioavailability are optimized before the drug reaches the market, rather than attempting to control crystallization during manufacturing.
Solution Approach 2:
The patent employs simple, inexpensive solvents (acetonitrile, ethyl acetate, ethanol, water) for crystallization that can be easily removed, leaving the stable crystal form. These volatile solvents serve as temporary mediators during preparation but are completely eliminated in the final product, simplifying the overall process while ensuring crystal form stability.
3Measurement precision
If x-ray powder diffraction is used for crystal form characterization, then identification precision is improved, but measurement time increases
Solution Approach 1:
The patent applies preliminary action by pre-establishing and documenting the characteristic X-ray powder diffraction patterns for Crystal form I and Crystal form II. These reference patterns are determined in advance and can be used for rapid identification and quality control, eliminating the need for time-consuming detailed characterization each time the crystal form needs to be verified.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Crystal forms of jervine exhibit strong inhibition of the Hedgehog signaling pathway with high bioavailability, effectively inhibiting tumor growth in xenograft models without significant side effects, making them promising candidates for antitumor drugs with improved pharmacokinetic profiles.
Implementation Method 1
The present invention provides crystal forms I and II of jervine, the crystal forms use X-ray powder diffraction with Cu-Ka radiation for characterization
Implementation Method 2
use X-ray powder diffraction with Cu-Ka radiation for characterization
Implementation Method 3
Jervine is a naturally occurring chemical that belongs to the group of steroidal jerveratrum alkaloids. It is also named 'jie li lu jian', 'jie li lu an', 'jie er wen' and 'suan li lu jian' in Chinese. It is a teratogen isolated from the corn lily (Veratrum californicum) that causes usually fatal birth defects. In 1957 the US Department of Agriculture started an eleven-year investigation which led to the identification of cyclopamine and jervine as the cause of the birth defect. It does so by inhibiting the hedgehog signaling pathway (Hh), thereby inhibit the activity of the protein.
Data Source
AI summary
The present invention provides two crystal forms of jervine and their preparation methods, and their application as antitumor agents. The preparation methods of these two crystal forms are simple, high yield and can be easily scaled to industry scale.